公司简介
- 股票代码
- GILD
- ISIN代码
- US3755581036
- 货币
- US Dollar (USD)
- IPO日期
- 1992-01-22
Gilead Sciences Inc (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi...
NASDAQHealthcareDrug Manufacturers - GeneralUSA
联系信息
- 公司地址
- 333 Lakeside Drive, Foster City, CA, United States, 94404
- 联系电话
- 650 574 3000
- 公司网站
- https://www.gilead.com
- 财年结束
- December
财务亮点
- 市值
- $999,999.99
- 毛利润（TTM）
- $999,999.99
- 股息收益率
- 2.44%
- 资产回报率（TTM）
- 13.29%
- EBITDA
- $999,999.99
- 收入（TTM）
- $999,999.99
'%3e%3cg%20id='mkuqs0y719954117'%20opacity='1'%20style='mix-blend-mode:normal'%3e%3cg%3e%3cg%3e%3cg%20id='mkuqs0y821269793_translate'%3e%3cg%20transform='matrix(1,0,0,1,1.1796999999999969,1.1796999999999969)'%3e%3cg%20id='mkuqs0y821269793'%20opacity='1'%20style='mix-blend-mode:normal'%3e%3cg%3e%3cg%3e%3cpath%20id='mkuqs0y821269793_fill_path'%20d='M48.82031,0c13.86456,0.00003%2026.37902,5.77981%2035.26611,15.06104l-14.05957,14.93896c0,0%20-23.81334,-0.16351%20-27.38623,0c-3.57289,0.16351%20-6.41943,3.32226%20-6.41943,6.93555c0.00025,3.71799%203.01438,6.73193%206.73242,6.73193h11.1792c9.24095,0.00003%2016.73231,7.4915%2016.73242,16.73242c-0.00013,9.24091%20-7.49148,16.7324%20-16.73242,16.73242h-20.8335l-4.76758,4.79004c5.90399,3.62636%2012.85185,5.71826%2020.28857,5.71826c21.43975,-0.00005%2038.82026,-17.38057%2038.82031,-38.82031c0,-5.66398%20-1.21347,-11.04437%20-3.39404,-15.896l7.29443,-7.75049c3.88606,7.0057%206.09961,15.06749%206.09961,23.64648c-0.00005,26.96259%20-21.85772,48.82026%20-48.82031,48.82031c-26.96263,0%20-48.82026,-21.85769%20-48.82031,-48.82031c0,-26.96266%2021.85765,-48.82031%2048.82031,-48.82031zM48.82031,10c-21.43982,0%20-38.82031,17.3805%20-38.82031,38.82031c0.00002,10.38271%204.07608,19.81347%2010.71533,26.7793l8.42773,-8.46729h24.98975c3.71809,-0.00003%206.73229,-3.01435%206.73242,-6.73242c-0.00011,-3.71808%20-3.01432,-6.7324%20-6.73242,-6.73242h-11.1792c-9.24089,0%20-16.73217,-7.49111%20-16.73242,-16.73193c0,-9.24104%207.49138,-16.73242%2016.73242,-16.73242h23.97949l3.65186,-3.53223c-6.20753,-4.21062%20-13.69873,-6.67088%20-21.76465,-6.6709z'%20fill-rule='evenodd'%20fill='rgb(109,%20211,%20165)'%20fill-opacity='1'%20style='mix-blend-mode:normal'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3canimateTransform%20href='%23mkuqs0y821269793'%20attributeName='transform'%20type='translate'%20values='48.8203%2048.8203;48.8203%2048.8203;48.8203%2048.8203;48.8203%2048.8203'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='sum'%20fill='freeze'%3e%3c/animateTransform%3e%3canimateTransform%20href='%23mkuqs0y821269793'%20attributeName='transform'%20type='scale'%20values='1%201;0.6%200.6;1%201;1%201'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='sum'%20fill='freeze'%3e%3c/animateTransform%3e%3canimateTransform%20href='%23mkuqs0y821269793'%20attributeName='transform'%20type='translate'%20values='-48.8203%20-48.8203;-48.8203%20-48.8203;-48.8203%20-48.8203;-48.8203%20-48.8203'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='sum'%20fill='freeze'%3e%3c/animateTransform%3e%3canimate%20href='%23mkuqs0y821269793'%20attributeName='opacity'%20values='1;0;1;1'%20dur='1.3s'%20repeatCount='indefinite'%20calcMode='spline'%20keyTimes='0;0.51;0.99;1'%20keySplines='0.5%200.35%200.15%201;0.5%200.35%200.15%201;0.5%200.35%200.15%201'%20additive='replace'%20fill='freeze'%3e%3c/animate%3e%3c/svg%3e)